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Strengths and limitations of this study
 ► The Brazilian polycystic ovary syndrome (PCOS) 
study will cover all regions of Brazil and use a broad 
approach to collect information on different demo-
graphic, lifestyle and health aspects.
 ► The prospective study design and standardised pro-
cedures allow exploration of clinical, genetic and 
epigenetic traits.
 ► A control group matched by age, geographical re-
gion and socioeconomic status will adhere to the 
same clinical protocol as the PCOS group.
 ► The clinical setting may represent a referral bias, 
since the prevalence of more severe cases may be 
higher than in population studies.
 ► The study population may be socioeconomically 
skewed given the inclusion of women strictly from 
the public healthcare system.
AbStrACt
Introduction Brazil is a large country, with a population 
of mixed ethnic background and broad variation in 
dietary and physical activity traits across its five main 
regions. Because data on Brazilian women with polycystic 
ovary syndrome (PCOS) are still scarce, a nation-wide 
collaborative study was designed to determine the 
prevalence of metabolic and reproductive abnormalities 
and the presence of anxiety and depression in Brazilian 
women with PCOS. In addition, the study aims at 
describing how these characteristics are distributed 
across PCOS phenotypes and at detecting associations 
with regional demographic and lifestyle aspects, genetic 
variants, and epigenetic markers.
Methods and analysis The Brazilian PCOS study is being 
conducted in the outpatient clinics of eight university 
hospitals within the public healthcare network (Unified 
Health System) across the country. Additional centres will 
be included following completion of the research ethics 
approval process. The sample includes women with PCOS 
according to Rotterdam criteria at inclusion in the study 
and a control group of healthy women matched by age, 
socioeconomic status and geographical region. Data will 
be collected in each centre and incorporated into a unified 
cloud database. Clinical, demographic, socioeconomic, 
psychological, metabolic, epigenetic and genotypic 
variables will be evaluated. The data resulting from this 
study will be useful to guide specific public strategies 
for primary and secondary prevention of metabolic and 
reproductive comorbidities in the PCOS population of 
Brazil.
Ethics and dissemination The study protocol was 
approved by each local Research Ethics Committee. 
Written informed consent will be obtained from each 
participant. During data collection, analysis and 
publication, care will be taken to ensure confidentiality of 
participant information. Study results will be published in 
peer-reviewed journals and disseminated at international 
conferences. This research protocol was registered 
with the Research Ethics Committee of HCPA, through 
Plataforma Brasil.
trial registration number CAAE 18082413.9.1001.5327
IntroduCtIon
Polycystic ovary syndrome (PCOS) is a 
complex disease with heterogeneous clinical 
presentation, characterised by chronic anovu-
lation and hyperandrogenism. It is the most 
common endocrine condition in women of 
reproductive age, with prevalence ranging 
from 8% to 13% in that age group.1 2 PCOS 
is associated with reproductive disorders and 
metabolic and cardiovascular disturbances 
including insulin resistance, obesity, hyper-
tension, diabetes and dyslipidaemia.3 Current 
evidence suggests that PCOS is a polygenic, 
multifactorial disorder, and that its patho-
genesis and clinical presentation are influ-
enced by both environmental risk factors 
and genetic susceptibility; however, a causal 
genetic pathway has not been identified until 
the present moment.4 Among environmental 
factors, lifestyle aspects such as an inappro-
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Figure 1 Flow chart of inclusion and study procedures.
contribute to central adiposity and metabolic comorbidi-
ties, play an important role in the pathogenesis of PCOS.3
Information regarding the prevalence and severity of 
PCOS is still lacking in many areas of the world, espe-
cially in low-income and middle-income regions such as 
Africa and South America.1 5 In Brazil, previous works 
have described the characteristics of small PCOS samples, 
reporting a range of metabolic, cardiovascular and 
inflammatory alterations.6–11 However, a broad study to 
gather nation-wide data is still missing.
Taking into account the continental dimensions of 
Brazil, the miscegenation of its population and the great 
variability in dietary and physical activity patterns across 
its regions, the aim of the present study is to determine 
the prevalence of metabolic and reproductive abnor-
malities and the presence of anxiety and depression in 
Brazilian women with PCOS. In addition, the study aims 
at identifying how these characteristics are distributed 
across PCOS phenotypes and whether they are associated 
with regional demographic and lifestyle aspects, genetic 
variants and epigenetic markers. Our hypothesis is that 
the prevalence of comorbidities and PCOS phenotypes 
may vary in different regions of the country, reflecting the 




This case–control study—the Brazilian PCOS study—
encompasses several Collaborating Centres across the 
country. The sample consists of women with PCOS and 
a control group of healthy participants matched by age, 
socioeconomic status and geographical region. The use 
of standardised procedures allows incorporation of the 
data collected in each centre into a unified database 
(figure 1). Participants will be recruited until 2021.
Setting
The first eight Collaborating Centres are distributed in 
the five Brazilian regions. The Coordinating Centre is 
located in the south, based at Universidade Federal do 
Rio Grande do Sul (Porto Alegre, South Region). Collab-
orating Centres include the following: in the southeast, 
Universidade Federal de Minas Gerais, Faculdade de 
Medicina, Universidade de São Paulo (USP), Facul-
dade de Medicina de Ribeirão Preto, USP and Instituto 
Estadual de Diabetes e Endocrinologia in Rio de Janeiro; 
in the north, Universidade Federal de Rondônia; in the 
northeast, Universidade Federal do Rio Grande do Norte; 
and in the midwest, Universidade Federal do Mato Grosso. 
Additional centres may join the study if they obtain local 
institutional ethics committee approval.
Sample
The study sample consists of women with PCOS receiving 
healthcare at university hospital outpatient clinics within 
the public healthcare network (Unified Health System). 
PCOS is diagnosed at inclusion using the Rotterdam 
criteria, and participants are further classified according 
to PCOS phenotypes, as follows: (1) classic PCOS—
women presenting oligo/amenorrhoea and/or anovu-
lation, clinical and/or biochemical hyperandrogenism, 
with or without polycystic ovary morphology (PCOM) 
(phenotypes A and B); (2) ovulatory PCOS—having 
clinical and/or biochemical hyperandrogenism, PCOM 
and regular menstrual cycles (phenotype C) and (3) 
normoandrogenic PCOS—defined by oligo/amenor-
rhoea, PCOM, absence of clinical hyperandrogenism and 
normal androgen levels (phenotype D).12
Non-PCOS control participants are recruited in each 
Collaborating Centre through public advertisement or 
among women consulting for contraception, vaccination 
or reasons not related with reproductive diseases. This 
control group will allow detection of regional and ethnic 
characteristics requiring adjustment and characterisation 
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Eligibility criteria
Participants in the case group must meet Rotterdam 
PCOS criteria at enrolment. Women aged 18–39 years, 
recruited at least 2 years after menarche, with body 
mass index (BMI) varying from 18.5 to 40 kg/m², and 
not taking any medicine that could interfere with meta-
bolic or hormonal assays are eligible for the study. Use 
of oral contraceptives must be stopped 3 months, and of 
metformin at least 2 months, before study enrolment. 
The same criteria apply to the control group.
Exclusion criteria
Type 1 diabetes, pregnancy, androgen-secreting tumours, 
Cushing syndrome, non-classical congenital adrenal 
hyperplasia, hyperprolactinaemia and thyroid illness 
without adequate control entail exclusion from the study. 
The same exclusion criteria apply to the control group.
Sample size estimation
The sample size was calculated assuming a prevalence of 
60% of the classic PCOS phenotype in Latin American 
women (Spritzer PM, PCOS metabolic profile and pheno-
types in Brazil and comparison with other Latin-Amer-
ican populations, 2019), with 95% CI, maximum absolute 
error of 5% and a design effect of 2. The case–control 
ratio was defined as 2:1. Based on these parameters, the 
sample size was estimated as 800 PCOS cases and 400 
controls. In addition, to ensure that the geographical 
distribution of the sample reflects the population of the 
five Brazilian regions, the following stratification was 
used: south (13.7%)—110 PCOS and 55 control partic-
ipants; southeast (41.5%)—332 PCOS and 167 control 
participants; northeast (28.4%)—227 PCOS and 113 
control participants; north (8.6%)—69 PCOS and 34 
control participants; and midwest (7.8%)—62 PCOS and 
31 control participants.
Ethics and dissemination
During data collection, care is taken to ensure confiden-
tiality of participants’ information. Interim analyses and 
the full final data set will be reported in scientific publica-
tions and at research conferences.
Patient and public involvement
There is no patient and public involvement in this study.
Prospective database
Standardised questionnaires are used to collect informa-
tion on demographic characteristics (age and self-reported 
skin colour), education, medical, family, reproductive 
history, lifestyle/behavioural factors, quality of life, medi-
cation/supplement inventory, alcohol consumption, 
cigarette smoking, dietary pattern, presence of asthma or 
migraine, comorbidities, menstrual pattern, presence of 
acne and/or hirsutism and obesity or overweight. Partic-
ipants are interviewed and examinations are performed 
at outpatient clinics in each centre (table 1). All partic-
ipants undergo a physical examination performed by a 
trained physician. The data are recorded in web-based 
forms. Data storage and management are centralised at 
the Coordinating Centre using a cloud service. Impor-
tantly, all data are immediately available after collection.
Education
Educational attainment is assessed through the number 
of years of successful formal education, described as years 
at school.
Socioeconomic status
Socioeconomic status is assessed using an instrument 
developed by the Brazilian Association of Market 
Research Institutes (Associação Brasileira de Institutos de 
Pesquisa de Mercado). Participants are classified into five 
socioeconomic groups: A, B, C, D and E, with A repre-
senting the highest socioeconomic level. This classifica-
tion is based on the responses to 15 questions that refer 
to variables such as educational attainment and items of 
home comfort.13
Alcohol intake
Alcohol consumption is self-reported: non-drinker (no 
drinking in the past year) or drinker. Participants are 
asked what type of alcohol (wine, beer, spirits, vodka, 
etc) they consume, the amount, and the frequency of 
consumption. After this detailed survey, the mean amount 
of alcohol (expressed as grams of alcohol consumed in 
a day) is estimated. Participants are then categorised 
as follows: low drinking (less than one drink per day), 
moderate drinking (less than two drinks per day), heavy 
drinking (more than seven drinks per week or three 
drinks per occasion) and binge drinking (four or more 
drinks on one drinking occasion).14
Smoking
For smokers, the number of cigarettes/day is registered. 
Former smokers are defined as individuals who report 
having quit smoking; they are also asked how old they 
were when they quit smoking. No minimum time since 
smoking cessation is employed in the definition of former 
smokers.15 16
Physical activity
Participants are asked about the type and frequency of the 
activity performed. The questions inquire about walking 
or riding a bicycle for commuting and about aerobic or 
anaerobic activities done for fitness. Specifically, partici-
pants are asked about physical training (walking, jogging, 
cycling, playing volleyball, basketball, handball, soccer, 
swimming, dancing and gym training). Besides their 
current habits, participants are surveyed about their phys-
ical activity in two past periods: from 12 to 18 years of age, 
and from 19 years until 1 year before study enrolment. 
For a given activity to be considered relevant, it must be 
performed for at least 10 uninterrupted minutes. Physical 
activity is classified according to its intensity, frequency 
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Table 1 Study outcomes, measurement instruments and assessment points
Outcome Measurement instrument and assessment points
Anthropometric measures Standardised, prospective measurements performed by trained personnel with the same 
calibrated equipment; weight, height, BMI, waist and hip circumference
Blood pressure/hypertension Two measurements using the same calibrated mercury manometer showing systolic blood 
pressure ≥130 mm Hg or diastolic blood pressure ≥80 mm Hg; medication use
Menstrual regularity Structured interview and classification according to International Federation of Gynaecology and 
Obstetrics nomenclature
Hirsutism Modified Ferriman-Gallwey scale administered by trained physician
Socioeconomic status Brazilian Association of Market Research Institutes questionnaire
Physical activity Short International Physical Activity Questionnaire
Dietary pattern Interview about frequency and amount of fruits and vegetables consumed daily and weekly
Psychological disorders Modified Self-Reporting Questionnaire 20
Quality of life WHO Quality of Life-BREF instrument
Dyslipidaemia History and blood tests—total cholesterol, HDL-C, LDL-C, triglycerides—medication use
Diabetes History and blood tests—fasting glucose—medication use
Metabolic syndrome Joint interim statement of the International Diabetes Federation; National Heart, Lung, and Blood 
Institute; American Heart Association; World Heart Federation; International Atherosclerosis 
Society; and International Association for the Study of Obesity; waist circumference, fast 
glucose, HDL-C, triglycerides and blood pressure levels
Polycystic ovarian 
morphology
Pelvic ultrasound with transvaginal probe whenever possible, any ovarian volume ≥10 cm³ in the 
absence of ovulatory follicle or cyst
Epigenetic changes Real-time quantitative PCR for microRNAs
Genotypic patterns Real-time PCR with TaqMan assays
BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Household activities such as cooking, dishwashing and 
house cleaning are also covered in this form, since they 
may represent a major physical activity for some women.
dietary pattern
The dietary pattern refers to the amount of fruits and 
vegetables participants eat on a normal day. Partici-
pants are first asked if they eat fruits and vegetables. If 
an affirmative answer is provided, the amount of fruits 
and vegetables consumed on a day is estimated. In addi-
tion, information is recorded on the daily and weekly 
frequency of fruit and vegetable consumption. Eating five 
or more portions of fruits and vegetables per day, 5–7 days 
in a week, is defined as a marker of healthy eating.19 20
Psychological assessment
Because patients with PCOS may have an increased 
propensity to psychological disorders,21 the modified 
Self-Reporting Questionnaire (SRQ-20) is used to deter-
mine the probability of psychological distress, mainly 
anxiety and depression. The SRQ-20 is recommended 
by the WHO for this purpose, and a validated Brazilian 
Portuguese version is available.22 Although the ideal 
cut-off is largely under debate, for the present sample a 
score >7 points in the SRQ-20 was established as the best 
estimate for the presence of a non-psychotic disorder. 
This cut-off had 86% sensitivity and 89% specificity in a 
Brazilian study including a population of which 54% were 
women. In that study, the discriminant power of SRQ-20 
for psychiatric screening was 0.9, and Cronbach's alpha 
was 0.86.23 24 Also, quality of life is assessed using the WHO 
Quality of Life-BREF instrument.25 The same instruments 
will be administered to the control group.
reproductive history and comorbidities
Women are asked about their age at menarche, the 
frequency and regularity of menses, use of medication to 
regulate menses, and the date of the last three menstrual 
periods. Menstrual pattern is then classified as regular, 
frequent, infrequent or amenorrhoea, according to the 
International Federation of Gynaecology and Obstetrics 
system.26 The use of hormonal contraception or any type 
of hormone therapy is verified by asking participants 
to show the medication box or the medical prescrip-
tion. The number of years of contraceptive use is also 
recorded. Information is collected on the use of non-hor-
monal contraceptive methods and the age at which the 
contraceptive method was started.
Obstetric history is assessed by asking about the number 
of pregnancies, miscarriages, term and preterm births, 
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and preeclampsia in any pregnancy. Information on other 
former medical intercurrences in pregnancy is collected 
using an open question. Information is also collected 
about offspring gestational age, weight, and length at 
birth and about offspring with birth weight >4 kg.
The participants are then asked whether they take 
medication or have a known diagnosis of hypertension, 
diabetes and dyslipidaemia.
Family history
Participants are asked about diseases affecting family 
members. All diseases mentioned are recorded, but 
direct questions are asked about the following: hyperten-
sion, cardiovascular disease (defined as an acute myocar-
dial infarction or angina pectoris), diabetes, thrombosis 
or pulmonary thromboembolism, infertility, hirsutism or 
thinning hair in women, and obesity.
Anthropometric measurements
Participants undergo a physical examination performed 
by a trained physician. Weight and height measure-
ments are performed without shoes or heavy clothing. 
Weight is measured using a mechanical scale and height 
is measured using a stadiometer. Waist circumference is 
measured at the midpoint between the iliac crest and the 
last rib. Hip circumference is measured at the widest point 
of the relaxed abdomen. For both measures, participants 
are asked to stand with feet together and arms hanging at 
the sides. All these measures are taken twice, and a mean 
value is computed.
blood pressure measurements
Standardised blood pressure measurements are 
performed twice, using the same calibrated mercury 
manometer. The mean of both assessments is used in 
the analysis. Hypertension is confirmed by asking about 
a previous diagnosis of hypertension or use of antihyper-
tensive medication, or else identified during the physical 
examination in the presence of systolic blood pressure 
≥130 mm Hg or diastolic blood pressure ≥80 mm Hg.27 28
hirsutism and acne
Hirsutism is assessed with the modified Ferriman-Gallwey 
scale. The score is registered as a continuous variable. A 
score of 8 points or more indicates hirsutism.29 Hirsutism 
score is initially assigned by a trained investigator. After 
that, the participant provides her own self-reported score 
using a printed guide showing body areas. Shaved areas 
are tagged as ‘shaved’ and are taken into account in the 
analysis.
In the next step of the physical examination, the physi-
cian records the presence of acanthosis nigricans, galac-
torrhoea, reddish-purple streaks, acne and androgenetic 
alopecia. Acne is classified as follows: grade I (presence 
of non-inflammatory lesions, comedones only), grade II 
(presence of inflammatory lesions such as pustules and 
skin redness plus comedones), grade III (presence of 
widely distributed larger pustules) and grade IV (presence 
of cysts, nodular pustules and abscesses, with moderate 
to severe scarring).30 Alopecia is classified according to 
severity as type I, II or III.31
blood and saliva sampling
Blood samples are collected from all participants between 
08:00 and 10:00 after an overnight fast of 10–12 hours, 
during the early follicular phase of the menstrual cycle or 
at a random day in case of oligo/amenorrhoea. Blood is 
quickly centrifuged at 1036g for 8 min at room tempera-
ture and serum is separated and stored in aliquots at 
−80°C for future hormonal and epigenetic analyses. 
Additional drop samples are collected in FTA gene cards 
(Whatman FTA) and stored at room temperature for 
genetic analysis. These samples are regularly transferred 
to the Coordinating Centre in the city of Porto Alegre for 
processing, and will constitute a bio-repository.
Salivary samples are obtained at the mid-luteal phase of 
the menstrual cycle using a chewing roll and a collector 
tube especially designed for salivary hormonal tests 
(Salivette, Sarstedt, Nümbrecht, Germany). The tubes 
are centrifuged at 1000g for 2 min and stored at −20°C for 
subsequent progesterone assays.
dyslipidaemia
History of dyslipidaemia is defined by self-reported hyper-
cholesterolaemia and/or use of anti-cholesterol drugs. 
Blood tests are also performed to measure total choles-
terol (TC) and fractions and triglyceride levels.
diabetes and metabolic syndrome
Diabetes is determined by self-report, use of antidia-
betic drugs or a fasting blood glucose level of 126 mg/
dL or higher. Metabolic syndrome is defined as the pres-
ence of at least three of the following components: waist 
circumference >88 cm, high-density lipoprotein choles-
terol (HDL-C) level <50 mg/dL, triglyceride (TG) level 
of 150 mg/dL or higher, blood pressure ≥130/85 mm Hg 
and glucose level of 100 mg/dL or higher.32
Pelvic ultrasound
A pelvic ultrasound image is obtained from all partici-
pants at each centre. The preferred method is the trans-
vaginal approach, considered to have the best sensitivity 
and specificity for evaluation of the uterus and ovaries. 
The transabdominal procedure is used for participants 
with no previous vaginal intercourse. Ultrasound exam-
ination is performed during the follicular phase in partic-
ipants with regular menses or on any day in those with 
oligo/amenorrhoea. Ovarian and uterine volumes and 
the number of antral follicles in each ovary are recorded. 
Ovarian volume ≥10 cm3 in at least one ovary, in the 
absence of corpus luteum, cyst or dominant follicle, will 
be considered as PCOM.33
Assays
TC, HDL-C, TGs and fasting glucose levels will be deter-
mined by colorimetric-enzymatic methods in each centre. 
Low-density lipoprotein cholesterol (LDL-C) is estimated 
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− (HDL-C +TG/5)). Hormone determinations will be 
performed at the Coordinating Centre. Steroid hormone 
binding globulin (SHBG), insulin and 25‐hydroxyvitamin 
D (25(OH)D) levels will be measured by chemilumines-
cence (Abbott Architect, IL, USA), with sensitivity of 
0.02 nmol/L, 1.0 μU/mL and 1.6 ng/mL, respectively. The 
intra-assay and interassay coefficients of variation (CVs) 
for SHBG, insulin and 25(OH)D are ≤5.2% and≤9.5%, 
≤4.2% and ≤5.2%, and ≤5.1% and≤7.1%, respectively. 
Total testosterone (TT) is measured by high-performance 
liquid chromatography-tandem mass spectrometry, with 
a sensitivity of 7.0 ng/dL and intra-assay and interassay 
CVs of 4.5% and 4.7%, respectively. Androstenedione, 
dehydroepiandrosterone sulfate (DHEA-S) and 17 alpha 
hydroxyprogesterone (17α-OHP) are determined by 
radioimmunoassay (Beckman Coulter, Prague, Czech 
Republic) with sensitivity of 0.05 ng/mL, 12.33 ng/mL 
and 0.046 ng/mL, respectively. The intra-assay and inter-
assay CVs for androstenedione, DHEA-S and 17α-OHP 
are ≤7.5% and≤11.3%,≤5.2% and≤5.3%,≤7.8% and≤15
.7%, respectively. Free androgen index is estimated by 
dividing TT (nmol/L) by SHBG (nmol/L) × 100. Homeo-
stasis model assessment index is calculated by multiplying 
insulin (μIU/mL) by glucose (mmol/L) and dividing 
this product by 22.5. The lipid accumulation product 
index is calculated using the formula (waist (cm) − 58) 
× triglyceride concentration (mmol/L). Salivary proges-
terone and serum anti-Müllerian hormone (AMH) will be 
assayed after enrolment is completed.
Molecular analyses
For later epigenetic/microRNA analysis, serum samples 
are stored at −80°C. MicroRNA extraction will be 
made with a commercial kit (miRNeasy Serum/Plasma 
Advanced Kit, Qiagen, Venlo, The Netherlands). Real-
time quantitative PCR will be performed to determine 
relative expression levels of a panel of microRNAs that 
have been previously screened and expressed differen-
tially in PCOS women.34
DNA will be extracted from blood samples in FTA 
gene cards according to the manufacturer's instruc-
tions. Single nucleotide polymorphisms (SNP) will be 
assessed by real-time PCR using allelic discrimination 
assays with TaqMan MGB primers and probes (Applied 
Biosystems, ThermoFisher Scientific, Waltham, MA, 
USA).
Genotypic analyses will target genes related to endocrine 
and metabolic dysfunctions of PCOS, including androgen 
excess and metabolism, insulin resistance, metabolic 
syndrome and vitamin D metabolism, adipokines, inflam-
matory markers, hormone receptors, obesity and diabetes 
mellitus, hormone-binding proteins, lipoproteins, angio-
tensin, interleukins, β-adrenergic, Peroxisome prolifera-
tor-activated receptor (PPAR) family, cytochrome p450, 
irisin, kisspeptin, uncoupling protein family, and immu-
nological factors.35 36
Statistics
The Shapiro-Wilk normality test and descriptive statistics 
will be used to evaluate the distribution of data. Parametric 
variables will be described as mean and SD. Variables 
with non-parametric distribution will be log-transformed 
before statistical analysis and reported as geometric mean 
of their original units of measure. Non-parametric vari-
ables will be presented as median and IQR. Categorical 
data will be expressed as percentage and 95% CIs. Statis-
tical tests will be applied according to data distribution 
in the different groups under comparison (eg, control vs 
PCOS or across PCOS categories). The preferred statis-
tical tests will be χ2 test for heterogeneity to compare 
proportions; one-way analysis of variance (ANOVA), 
followed by Bonferroni post-hoc tests for parametric 
variables or their equivalent of non-parametric statistics 
(ie, Kruskal-Wallis test); co-variance analysis will also be 
considered (eg, analysis of covariance) to examine the 
influence of variables such as age and BMI.
The association of demographic, anthropometric and 
metabolic variables with lifestyle habits and epigenetic 
markers will be investigated by unadjusted analyses, multi-
variate models as well as stratified by groups. An important 
focus of these analyses is the potential heterogeneity of 
risk relationships in different regions and PCOS catego-
ries. Therefore, interactions will be tested when appro-
priate. Logistic regression will be preferred to estimate 
the OR for the associations under the investigation.
Regarding molecular analyses, the agreement of geno-
type frequencies with Hardy-Weinberg equilibrium for 
each SNP will be analysed using the Pearson χ2 test. 
Lewontin’s D’ statistic for linkage disequilibrium will be 
calculated for each pair of polymorphisms, and haplo-
types will be inferred using the Phase 2.1 software, which 
uses Bayesian statistics. Linear trends will be tested to 
check for codominant effects of genotypes on scale data. 
The relationship between the outcome of interest and 
genotypes will be evaluated using ORs. All analyses will be 
performed in PASW Statistics for Windows, V.21.0 (SPSS, 
Chicago, IL, USA). All tests will be two-tailed and signifi-
cance will be accepted at a p value<0.05.
dISCuSSIon
This is the first nation-wide study of PCOS in Brazil, a large 
country with a population of mixed ethnic background 
and marked variation in dietary and cultural traits. These 
characteristics provide a unique opportunity to investi-
gate the association of lifestyle, environmental, genetic 
and epigenetic factors with the phenotypic expression of 
PCOS. We hypothesise that the prevalence of metabolic 
and reproductive features in women with PCOS may vary 
in different regions of the country and in different PCOS 
phenotypes.
The aetiology of PCOS is multifactorial, and investiga-
tors have focused on novel pathogenic mechanisms.3 34 35 In 
this sense, in the present study, we are collecting genomic 
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epigenetic markers associated with PCOS and/or asso-
ciated comorbidities. These analyses will be stratified 
according to the geographical region and demographic 
profile of participants, which will allow an unbiased 
assessment of genomic and epigenetic variations.
In addition, this study will generate data that will allow 
us to estimate the prevalence of obesity and unhealthy 
lifestyles to be compared in women of reproductive age 
from different regions of the country. These cardiomet-
abolic modifiable risk factors will be evaluated in PCOS 
participants together with demographic, metabolic, 
genomic and epigenetic factors to determine how these 
variables cluster in a population of mixed genetic back-
ground. Another important aspect is the opportunity to 
investigate the psychological impact of PCOS.
To avoid methodological inconsistency in molecular 
analyses, we established a strict protocol of FTA gene 
cards, blood and saliva collection, storage and trans-
portation to a single centre for analysis. In turn, pelvic 
ultrasound will be performed at each study site by a local 
expert using the best available local equipment. This 
invariably creates some inter-centre variability in terms 
of antral follicle count,37 and may introduce detection 
bias in the inter-regional comparison of PCOS pheno-
types. To overcome this limitation, we included measure-
ments of ovarian volume, which produce less variability 
and have acceptable validity to assess ovarian polycystic 
morphology according to the Rotterdam criteria.12 33 
We also plan to measure serum AMH levels, a reliable 
surrogate of ovarian polycystic morphology.38 AMH levels 
will be assayed at a single laboratory using stored serum 
samples. In addition, measuring salivary progesterone in 
the luteal phase of women with regular menstrual cycles 
will allow us to ascertain ovulation and better characterise 
the control group and ovulatory PCOS phenotype C.
Another limitation of this study is the clinical setting, 
which may represent a referral bias, since the prevalence 
of more severe cases may be higher than in population 
studies.39 In addition, women with PCOS referred to a 
secondary/tertiary healthcare unit, who agree to partic-
ipate in a comprehensive examination, may constitute a 
selected population regarding both socioeconomic status 
and severity of symptoms. However, this case–control 
study will benefit from the planned complete characteri-
sation of clinical and laboratorial features of PCOS as well 
as the exclusion of other hyperandrogenic conditions. 
Also, the comparison with a control group, which will be 
matched by age and geographical region and submitted 
to the same protocol as PCOS participants, including 
progesterone levels and pelvic ultrasonography, may 
be regarded as a strength; this will allow adjustment for 
regional and ethnic characteristics, if necessary, and 
enable characterisation of genotype distribution in the 
Brazilian population.
In conclusion, the Brazilian PCOS study will be useful to 
guide specific public strategies for primary and secondary 
prevention of metabolic and reproductive comorbidities 
in the PCOS population of Brazil. Beyond Brazil, the data 
to be produced might also add information regarding the 
impact of environmental, epigenetic and ethnicity factors 
on the clinical expression of PCOS.
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